<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/82321AD2-CD2E-456C-9395-59CF155A3EC8"><gtr:id>82321AD2-CD2E-456C-9395-59CF155A3EC8</gtr:id><gtr:name>Sanofi</gtr:name><gtr:address><gtr:line1>174 avenue de France</gtr:line1><gtr:line4>Paris cedex 13</gtr:line4><gtr:postCode>75635</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>France</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/46DB0EB7-3DE7-4E45-BFC0-2E7255E49A4B"><gtr:id>46DB0EB7-3DE7-4E45-BFC0-2E7255E49A4B</gtr:id><gtr:name>Bristol-Myers Squibb</gtr:name><gtr:address><gtr:line1>Bristol-Myers Squibb</gtr:line1><gtr:line2>311 Pennington Rocky Hill Road</gtr:line2><gtr:region>Outside UK</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/4D643118-D00D-43C5-A6C4-6035292F169C"><gtr:id>4D643118-D00D-43C5-A6C4-6035292F169C</gtr:id><gtr:name>Novartis</gtr:name></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/AE58F21F-3622-4382-97BB-1359BD183E9F"><gtr:id>AE58F21F-3622-4382-97BB-1359BD183E9F</gtr:id><gtr:name>University of Glasgow</gtr:name><gtr:department>Unlisted</gtr:department><gtr:address><gtr:line1>University Avenue</gtr:line1><gtr:line4>Glasgow</gtr:line4><gtr:postCode>G12 8QQ</gtr:postCode><gtr:region>Scotland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/AE58F21F-3622-4382-97BB-1359BD183E9F"><gtr:id>AE58F21F-3622-4382-97BB-1359BD183E9F</gtr:id><gtr:name>University of Glasgow</gtr:name><gtr:address><gtr:line1>University Avenue</gtr:line1><gtr:line4>Glasgow</gtr:line4><gtr:postCode>G12 8QQ</gtr:postCode><gtr:region>Scotland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>FELLOW</gtr:name></gtr:role><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/82321AD2-CD2E-456C-9395-59CF155A3EC8"><gtr:id>82321AD2-CD2E-456C-9395-59CF155A3EC8</gtr:id><gtr:name>Sanofi</gtr:name><gtr:address><gtr:line1>174 avenue de France</gtr:line1><gtr:line4>Paris cedex 13</gtr:line4><gtr:postCode>75635</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>France</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/46DB0EB7-3DE7-4E45-BFC0-2E7255E49A4B"><gtr:id>46DB0EB7-3DE7-4E45-BFC0-2E7255E49A4B</gtr:id><gtr:name>Bristol-Myers Squibb</gtr:name><gtr:address><gtr:line1>Bristol-Myers Squibb</gtr:line1><gtr:line2>311 Pennington Rocky Hill Road</gtr:line2><gtr:region>Outside UK</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/4D643118-D00D-43C5-A6C4-6035292F169C"><gtr:id>4D643118-D00D-43C5-A6C4-6035292F169C</gtr:id><gtr:name>Novartis</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/5677D250-0E2B-43EF-87C9-CAE76B0B9CAE"><gtr:id>5677D250-0E2B-43EF-87C9-CAE76B0B9CAE</gtr:id><gtr:firstName>Mhairi</gtr:firstName><gtr:surname>Copland</gtr:surname><gtr:roles><gtr:role><gtr:name>FELLOW</gtr:name></gtr:role><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=G84%2F6317"><gtr:id>5549EDA5-F7B1-42B9-8FB4-4FE7421DA9E4</gtr:id><gtr:title>Novel drug combinations for eradication of Ph+/Bcr-Abl+ haemopoietic stem cells in chronic myeloid leukaemia (CML)</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Fellowship</gtr:grantCategory><gtr:grantReference>G84/6317</gtr:grantReference><gtr:abstractText>Abstracts are not currently available in GtR for all funded research. This is normally because the abstract was not required at the time of proposal submission, but may be because it included sensitive information such as personal details.</gtr:abstractText><gtr:fund><gtr:end>2006-09-30</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2003-10-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>152860</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>Bristol-Myers Squibb</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>Hedgehog inhibitor clinical trial in CML</gtr:description><gtr:id>9E571C76-97AE-4C9F-9CFF-82A8BF891006</gtr:id><gtr:impact>Multi-disciplinary - NHS - university - industry</gtr:impact><gtr:outcomeId>G4iTw8aJkVR-1</gtr:outcomeId><gtr:piContribution>Principal investigator for Phase 1 clinical trial. Undertaking correlative laboratory studies for commercial clinical trial</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Novartis</gtr:collaboratingOrganisation><gtr:country>Global</gtr:country><gtr:description>Hedgehog Inhibitor and nilotinib to target CML stem cells</gtr:description><gtr:id>79DDE28C-8195-47D0-A3BF-1AB0BB283F4D</gtr:id><gtr:impact>Abstract submission and presentation at the American Society of Haematology 2009. Provision of preliminary data to allow PhD student to obtain independet funding for Clinical Research Fellowship from Chief Scientist's Office for Scotland</gtr:impact><gtr:outcomeId>18B3325E454-1</gtr:outcomeId><gtr:partnerContribution>Provision of research funding to support study. Joint patent application. Provision of hedgehog inhibitor LDE225 and tyrsoine kinase inhibitor nilotinib for in vitro and murine studies. Discussions ongoing to develop clinical trial for combination of LDE225 and nilotinib in the treatment of CML</gtr:partnerContribution><gtr:piContribution>Assessment of the Hedgehog inhibitor LDE225 in combination with nilotinib in CML in bith in vitro and in vivo murine studies. Ongoing development of clinical trial.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2007-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Bristol-Myers Squibb</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>Provision of Dasatinib</gtr:description><gtr:id>7FEF41D2-678F-4A1F-AF78-AE14C949AA0E</gtr:id><gtr:impact>This collaboration led to a number of publications as detailed in Section 2: Pubmed IDs: 16469872 16572205 18156496 19047139 19738029 In addition my PhD supervisor has gone on to receive a programme grant from CR-UK, one aim of which is to further investigate the mechanism of action of BMS-214662.</gtr:impact><gtr:outcomeId>260001E430E-1</gtr:outcomeId><gtr:partnerContribution>Availability of small molecule inhibitors dasatinib and BMS-214662 under Material Transfer Agreements has led to several publications and further ongoing studies.</gtr:partnerContribution><gtr:piContribution>Provision of dasatinib (BMS-354825), BMS-214662 and BMS225975 for preclinical studies under MTA</gtr:piContribution><gtr:sector>Private</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Sanofi</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:department>Genzyme Corporation</gtr:department><gtr:description>Assessment of plerixafor in combination with tyrosine kinase inhibitors in chronic myeloid leukaemia</gtr:description><gtr:id>B0109B12-F8A7-4BCA-B95E-F993917A9C5C</gtr:id><gtr:impact>Preliminary experiments ongoing. Planned abstract submission early 2010</gtr:impact><gtr:outcomeId>8E158A7A764-1</gtr:outcomeId><gtr:partnerContribution>Ability to develop new research programme targeting leukaemic stem cells with provision of plerixafor for in vitro use.</gtr:partnerContribution><gtr:piContribution>Assessment of plerixafor in combination with tyrosine kinase inhibitors in chronic myeloid leukaemia - MTA - Provision of Plerixafor for in vitro experiments</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2008-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>Developmental Therapeutics Consortium, EHA Satelitte symposium, London</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>A937109A-E274-4B3E-975B-396FB5272AD7</gtr:id><gtr:impact>Developmental Therapeutics Consortium, EHA satelitte symposium, London

improve collaborations</gtr:impact><gtr:outcomeId>hhfrD7R7xQY</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Other academic audiences (collaborators, peers etc.)</gtr:primaryAudience><gtr:year>2011</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>NCRI CML Working Party Scientific Meeting, Cambridge</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>AB574DAF-2FF1-4D0E-AD13-D6E0DC937B17</gtr:id><gtr:impact>presentation/talk

improved collaboroations</gtr:impact><gtr:outcomeId>ottALbnbgZL</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Other academic audiences (collaborators, peers etc.)</gtr:primaryAudience><gtr:year>2008</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Laboratory open day</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:id>AB8F7089-C9F9-41F2-A369-8A6A4452C3D9</gtr:id><gtr:impact>Short presentations and equipment demonstrations to patients, their families and donors to new laboratory

Ongoing fundraising for new laboratory</gtr:impact><gtr:outcomeId>78830B5EE11</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2008,2009</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>2nd National Conference:Haematological Malignancies, London</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>661B9F53-26C5-4550-A891-5FED6D4BDF09</gtr:id><gtr:impact>presentation/talk

improve collaborations</gtr:impact><gtr:outcomeId>bBd4amdwXox</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Other academic audiences (collaborators, peers etc.)</gtr:primaryAudience><gtr:year>2010</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>CML Stem Cell Workshop, Loiporsdorf.</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>3C687C3B-8806-4300-A595-BA064324F048</gtr:id><gtr:impact>CML stem cell workshop, loiporsdorf. Talk

improve collaborations</gtr:impact><gtr:outcomeId>SLwJ6o4abeE</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Other academic audiences (collaborators, peers etc.)</gtr:primaryAudience><gtr:year>2011</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>NCRI CML working party scientific meeting, manchester</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>E74DE162-AFE0-4F2B-8283-760424C9C9A7</gtr:id><gtr:impact>presentation/talk

improved collaborations</gtr:impact><gtr:outcomeId>AgnsqPWdpqR</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Other academic audiences (collaborators, peers etc.)</gtr:primaryAudience><gtr:year>2010</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Working conference on neoplastic stem cells, vienna</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>A0E5B33D-74ED-4D94-9131-274622EAE341</gtr:id><gtr:impact>working conference on neoplastic stem cells, vienna

improve collaborations</gtr:impact><gtr:outcomeId>Q7vVwv3vKm8</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Other academic audiences (collaborators, peers etc.)</gtr:primaryAudience><gtr:year>2011</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Paul O'Gorman Leukaemia Research Centre Newsletter</gtr:description><gtr:form>A magazine, newsletter or online publication</gtr:form><gtr:id>FF9ED1EF-2073-40D8-B85C-EF55FD4B83E8</gtr:id><gtr:impact>Writing articles about staff in group and ongoing research developments

Ongoing fundraising and informing the public about our research and raising awareness</gtr:impact><gtr:outcomeId>C9365C131B7</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Participants in your research and patient groups</gtr:primaryAudience><gtr:year>2008,2009</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>cml horizons 2012, leukaemia patients' advocates foundation, munich</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>AB3C06BC-0AB6-4B4F-BF9E-B3667F44268A</gtr:id><gtr:impact>cml horizons 2012, leukaemia patients' advocates foundation, munich. provided talk

improve collaborations</gtr:impact><gtr:outcomeId>TAWKktLERsf</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Other academic audiences (collaborators, peers etc.)</gtr:primaryAudience><gtr:year>2012</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>CML Biologic basis of therapy, European School of Hematology, Washington</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>C60E063C-6A33-4EE9-B923-D8DDCB9FA253</gtr:id><gtr:impact>CML, Biologic basis of therapy - talk

improved collaborations</gtr:impact><gtr:outcomeId>HMu74GKf8vf</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Other academic audiences (collaborators, peers etc.)</gtr:primaryAudience><gtr:year>2010</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Laboratory open day for Leukaemia Research Trust for Scotland</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:id>9FF2B6D4-F3DD-44E8-86EF-AF73B33FE7BE</gtr:id><gtr:impact>15 minute presentation to fundraisers about the ongoing work undertaken during my PhD

Further fudning obtained to total of &amp;pound;22000</gtr:impact><gtr:outcomeId>08289004606</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2006</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>ncri cml working party patient day, cardiff</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>4C6C9C3D-E9EE-47A0-8E8F-2FD80BCF93DA</gtr:id><gtr:impact>ncri cml working party patient day, cardiff. provided talk

improve collaborations</gtr:impact><gtr:outcomeId>S3G4KRZXivd</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Other academic audiences (collaborators, peers etc.)</gtr:primaryAudience><gtr:year>2011</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>cml - biologic basis of therapy, european school of hematology, estoril</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>1D4B79A7-D1A6-44AB-B890-BE9FD95F7818</gtr:id><gtr:impact>cml, biologic basis of therapy, european school of haematology, estorial - talk

improve collaborations</gtr:impact><gtr:outcomeId>Rj1uhD6JRYt</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Other academic audiences (collaborators, peers etc.)</gtr:primaryAudience><gtr:year>2011</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>188857</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>CSO Clinical Research Fellowship</gtr:description><gtr:end>2011-10-02</gtr:end><gtr:fundingOrg>Chief Scientist Office (CSO)</gtr:fundingOrg><gtr:id>6459AF44-B39B-45E6-910A-412AEB76D078</gtr:id><gtr:outcomeId>E36EC9519680</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2008-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>120000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>NCRRR</gtr:description><gtr:end>2016-09-02</gtr:end><gtr:fundingOrg>National Centre for the Replacement, Refinement and Reduction of Animals in Research (NC3Rs)</gtr:fundingOrg><gtr:id>BA63F34D-7E3D-4C06-9D60-B203D63383F1</gtr:id><gtr:outcomeId>TBzdqca56tD</gtr:outcomeId><gtr:sector>Private</gtr:sector><gtr:start>2012-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>77149</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Leukaemia and Lymphoma research Therapy Acceleration programme</gtr:description><gtr:end>2013-12-02</gtr:end><gtr:fundingOrg>Leukaemia and Lymphoma Research</gtr:fundingOrg><gtr:id>7C7DF21D-F131-4746-9CEC-E200029C1250</gtr:id><gtr:outcomeId>jeP48jkLrQn0</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>147752</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>The Hadwen Trust, research grant</gtr:description><gtr:end>2016-12-02</gtr:end><gtr:fundingOrg>Dr Hadwen Trust (DHT)</gtr:fundingOrg><gtr:id>984107E9-F21F-4D43-89A2-5EFFA922B042</gtr:id><gtr:outcomeId>UiS93BsRtAW</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>213632</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>The Wellcome Trust LTd, RESEARCH TRAINING FELLOW</gtr:description><gtr:end>2016-08-02</gtr:end><gtr:fundingOrg>Wellcome Trust</gtr:fundingOrg><gtr:fundingRef>100626/2/Z/12/Z</gtr:fundingRef><gtr:id>89A7C2DE-0D7B-4FF7-BBA4-3064F7250496</gtr:id><gtr:outcomeId>rZepLpyHurg0</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2013-08-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>231168</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Wellcome</gtr:description><gtr:end>2016-09-02</gtr:end><gtr:fundingOrg>Wellcome Trust</gtr:fundingOrg><gtr:id>CC530FC6-C32B-43E0-A53B-FD15F9FDB37E</gtr:id><gtr:outcomeId>G5ahmGsiuF6</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2012-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>390000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>CSO Senior Clinical Fellowship Scheme</gtr:description><gtr:end>2013-03-02</gtr:end><gtr:fundingOrg>Chief Scientist Office (CSO)</gtr:fundingOrg><gtr:id>18F9E533-FAE4-4D15-AFB2-E5BAF6C634CE</gtr:id><gtr:outcomeId>9F29E61E4590</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2009-04-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>24000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Chief Scientist Office</gtr:description><gtr:end>2006-12-02</gtr:end><gtr:fundingOrg>Chief Scientist Office (CSO)</gtr:fundingOrg><gtr:id>5527945B-13E8-43D6-BEA3-F10247A46D27</gtr:id><gtr:outcomeId>ZpkY25jUGqF</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2006-06-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>217599</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Leukaemia and Lymphoma Research Project Grant</gtr:description><gtr:end>2014-06-02</gtr:end><gtr:fundingOrg>Leukaemia and Lymphoma Research</gtr:fundingOrg><gtr:id>64B906DB-591F-49D9-AB53-170E0B0335C9</gtr:id><gtr:outcomeId>bxiVADNdni10</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2011-07-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>200000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>CR-UK</gtr:description><gtr:end>2016-07-02</gtr:end><gtr:fundingOrg>Cancer Research UK</gtr:fundingOrg><gtr:id>40C08584-4F27-43F7-A92C-E366C43C872B</gtr:id><gtr:outcomeId>kq5G7YffGoh</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2012-08-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>7629363A-7846-458F-9232-53869EE29691</gtr:id><gtr:title>Dasatinib (BMS-354825) targets an earlier progenitor population than imatinib in primary CML but does not eliminate the quiescent fraction.</gtr:title><gtr:parentPublicationTitle>Blood</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c20747e3a9cc18ff9bebf8d652277db8"><gtr:id>c20747e3a9cc18ff9bebf8d652277db8</gtr:id><gtr:otherNames>Copland M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>0006-4971</gtr:issn><gtr:outcomeId>9833966999A</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2DD2A9CF-4AAF-4CE3-97D5-FFE9CA96541C</gtr:id><gtr:title>Effects of dasatinib on SRC kinase activity and downstream intracellular signaling in primitive chronic myelogenous leukemia hematopoietic cells.</gtr:title><gtr:parentPublicationTitle>Cancer research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/45ea88f61b8ec80a0139768b16725e98"><gtr:id>45ea88f61b8ec80a0139768b16725e98</gtr:id><gtr:otherNames>Konig H</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0008-5472</gtr:issn><gtr:outcomeId>6A685BE3E3F</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>89D46AD2-C216-4914-8BB7-92DBF2184937</gtr:id><gtr:title>Cancerous inhibitor of PP2A (CIP2A) at diagnosis of chronic myeloid leukemia is a critical determinant of disease progression.</gtr:title><gtr:parentPublicationTitle>Blood</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/726ca869ae597731dd3f2a4fb0265089"><gtr:id>726ca869ae597731dd3f2a4fb0265089</gtr:id><gtr:otherNames>Lucas CM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0006-4971</gtr:issn><gtr:outcomeId>kr21WUguX64</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B56EB538-15CD-4412-907B-AD648C570E90</gtr:id><gtr:title>Microfluidic single cell arrays to interrogate signalling dynamics of individual, patient-derived hematopoietic stem cells.</gtr:title><gtr:parentPublicationTitle>Lab on a chip</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d0f4a99c73da6ecff1f3a07aba062eec"><gtr:id>d0f4a99c73da6ecff1f3a07aba062eec</gtr:id><gtr:otherNames>Faley SL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>1473-0189</gtr:issn><gtr:outcomeId>63C072F1796</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C11B5116-7387-4E68-8A12-6E23F2C286F3</gtr:id><gtr:title>Chronic myeloid leukemia stem cells display alterations in expression of genes involved in oxidative phosphorylation.</gtr:title><gtr:parentPublicationTitle>Leukemia &amp; lymphoma</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e919ccea91e0ca7fc34a9075d5c259d7"><gtr:id>e919ccea91e0ca7fc34a9075d5c259d7</gtr:id><gtr:otherNames>Flis K</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1026-8022</gtr:issn><gtr:outcomeId>pm_14738_28_22616753</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B6DDB9C2-4D47-47CB-9B46-3D5BB1EFB2CB</gtr:id><gtr:title>Intermittent exposure of primitive quiescent chronic myeloid leukemia cells to granulocyte-colony stimulating factor in vitro promotes their elimination by imatinib mesylate.</gtr:title><gtr:parentPublicationTitle>Clinical cancer research : an official journal of the American Association for Cancer Research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c3f9e15681284c6865d6d2b96ffdbbc9"><gtr:id>c3f9e15681284c6865d6d2b96ffdbbc9</gtr:id><gtr:otherNames>J?rgensen HG</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>1078-0432</gtr:issn><gtr:outcomeId>79240DE5862</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9C739EE2-3C84-44B4-99DD-82F04ABB3D3D</gtr:id><gtr:title>BMS-214662 potently induces apoptosis of chronic myeloid leukemia stem and progenitor cells and synergizes with tyrosine kinase inhibitors.</gtr:title><gtr:parentPublicationTitle>Blood</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c20747e3a9cc18ff9bebf8d652277db8"><gtr:id>c20747e3a9cc18ff9bebf8d652277db8</gtr:id><gtr:otherNames>Copland M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0006-4971</gtr:issn><gtr:outcomeId>62E347C96F7</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>BDC59FA2-C6E8-4EF2-838D-2AFE0BA0BF0B</gtr:id><gtr:title>The MEK inhibitor PD184352 enhances BMS-214662-induced apoptosis in CD34+ CML stem/progenitor cells.</gtr:title><gtr:parentPublicationTitle>Leukemia</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/86e6f4cc5f28e75d0ac2d7d32e30b8fc"><gtr:id>86e6f4cc5f28e75d0ac2d7d32e30b8fc</gtr:id><gtr:otherNames>Pellicano F</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0887-6924</gtr:issn><gtr:outcomeId>aiokNudLnQj</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>687F4956-79D2-4307-B8F3-6C5FD4D34E2D</gtr:id><gtr:title>BCR-ABL activity and its response to drugs can be determined in CD34+ CML stem cells by CrkL phosphorylation status using flow cytometry.</gtr:title><gtr:parentPublicationTitle>Leukemia</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a870925ac016ad80b9494e829a777bce"><gtr:id>a870925ac016ad80b9494e829a777bce</gtr:id><gtr:otherNames>Hamilton A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>0887-6924</gtr:issn><gtr:outcomeId>6C8336D7F82</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>525104B7-48AB-4360-A74B-EF332AAAB9C4</gtr:id><gtr:title>Complete molecular responses are achieved after reduced intensity stem cell transplantation and donor lymphocyte infusion in chronic myeloid leukemia.</gtr:title><gtr:parentPublicationTitle>Blood</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/12b2dd3f7fc03f7b3cf973567d55ddfa"><gtr:id>12b2dd3f7fc03f7b3cf973567d55ddfa</gtr:id><gtr:otherNames>Heaney NB</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0006-4971</gtr:issn><gtr:outcomeId>8F705A4AD20</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>562BFF0D-302C-4726-B81F-3B06EB713908</gtr:id><gtr:title>Quantitative proteomics analysis of BMS-214662 effects on CD34 positive cells from chronic myeloid leukaemia patients.</gtr:title><gtr:parentPublicationTitle>Proteomics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8763b0fa3b79abc2063c1e47712f5fe9"><gtr:id>8763b0fa3b79abc2063c1e47712f5fe9</gtr:id><gtr:otherNames>Balabanov S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1615-9853</gtr:issn><gtr:outcomeId>pm_14738_28_23184491</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>91A6742D-A031-4FAA-9235-0C99DBDCBC12</gtr:id><gtr:title>Chronic myelogenous leukemia stem cells: What's new?</gtr:title><gtr:parentPublicationTitle>Current hematologic malignancy reports</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c20747e3a9cc18ff9bebf8d652277db8"><gtr:id>c20747e3a9cc18ff9bebf8d652277db8</gtr:id><gtr:otherNames>Copland M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>1558-8211</gtr:issn><gtr:outcomeId>S4GLTLV6AB7</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>252313A6-C3DA-4A95-8D07-88A95E972FBB</gtr:id><gtr:title>Hypusination of eukaryotic initiation factor 5A (eIF5A): a novel therapeutic target in BCR-ABL-positive leukemias identified by a proteomics approach.</gtr:title><gtr:parentPublicationTitle>Blood</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8763b0fa3b79abc2063c1e47712f5fe9"><gtr:id>8763b0fa3b79abc2063c1e47712f5fe9</gtr:id><gtr:otherNames>Balabanov S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0006-4971</gtr:issn><gtr:outcomeId>678A1B41D25</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>735EB6D4-9E56-44CA-90FE-337936CC28AE</gtr:id><gtr:title>BMS-214662 induces mitochondrial apoptosis in chronic myeloid leukemia (CML) stem/progenitor cells, including CD34+38- cells, through activation of protein kinase Cbeta.</gtr:title><gtr:parentPublicationTitle>Blood</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/86e6f4cc5f28e75d0ac2d7d32e30b8fc"><gtr:id>86e6f4cc5f28e75d0ac2d7d32e30b8fc</gtr:id><gtr:otherNames>Pellicano F</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0006-4971</gtr:issn><gtr:outcomeId>F2733F873DE</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>22793C10-DC3E-4B03-B3C1-E8C81F9A3622</gtr:id><gtr:title>Intracellular protein trafficking kinetics in chronic myeloid leukemia stem cells using a microfluidic platform.</gtr:title><gtr:parentPublicationTitle>Integrative biology : quantitative biosciences from nano to macro</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f447cfe29c28b646bf475452c6f5bdc4"><gtr:id>f447cfe29c28b646bf475452c6f5bdc4</gtr:id><gtr:otherNames>Faley S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1757-9694</gtr:issn><gtr:outcomeId>pm_14738_28_22344285</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7B806F69-43DA-47FB-A58E-267582942824</gtr:id><gtr:title>Ikaros deletions are associated with poor prognosis in acute lymphoblastic leukemia.</gtr:title><gtr:parentPublicationTitle>Future oncology (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c20747e3a9cc18ff9bebf8d652277db8"><gtr:id>c20747e3a9cc18ff9bebf8d652277db8</gtr:id><gtr:otherNames>Copland M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>1479-6694</gtr:issn><gtr:outcomeId>A3C3DFD1E5E</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G84/6317</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>7C58A707-1BF6-4573-A44F-30B271C80813</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Cancer</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>8F896112-5A04-4A11-A9F0-2B446D9AAC8A</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>5.1  Pharmaceuticals</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>